Market Spotlight: Osteoarthritis and Osteoarthritis Pain
Market Spotlight: Osteoarthritis and Osteoarthritis Pain
$1,318.00
This Market Spotlight report covers the Osteoarthritis and Osteoarthritis Pain market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Osteoarthritis and Osteoarthritis Pain market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2019, there were 320.7 million prevalent cases of osteoarthritis (knee or hip) in adults aged 30 years and older worldwide, and forecasts that number to increase to 367.7 million prevalent cases by 2028.
- The global prevalence of osteoarthritis in adults aged 30 years and older is estimated to be 8.2%. The approved drugs in the osteoarthritis space focus on a wide variety of targets. The majority of these therapies are administered via the oral route, with the remainder being topical, intraarticular, and transdermal formulations.
- The majority of industry-sponsored drugs in active clinical development for osteoarthritis are in Phase II. Therapies in development for osteoarthritis focus on a wide variety of targets. The largest proportion of pipeline drugs are administered via the intraarticular route.
- High-impact upcoming events for drugs in the osteoarthritis space comprise topline Phase II, Phase IIb, and Phase III trial results. The overall likelihood of approval of a Phase I osteoarthritis and osteoarthritis pain asset is 9.1%, and the average probability a drug advances from Phase III is 50%. Drugs, on average, take 13.2 years from Phase I to approval in the osteoarthritis and osteoarthritis pain space, as well as in the overall rheumatology (non autoimmune) space.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for osteoarthritis have been in the early and mid-phases of development, with 59% of trials in Phase I–II, and 41% in Phase III–IV.
- The US has a substantial lead in the number of osteoarthritis clinical trials globally. The UK leads the major European markets, while South Korea has the top spot in Asia.
- Clinical trial activity in the osteoarthritis space is dominated by completed trials. Pfizer has the highest number of completed clinical trials for osteoarthritis, with 124 trials.
- Pfizer leads industry sponsors with the highest overall number of clinical trials for osteoarthritis.
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
9 TREATMENT
9 Non-pharmacological treatment
9 Pharmacological treatment
10 Surgery
11 EPIDEMIOLOGY
14 MARKETED DRUGS
18 PIPELINE DRUGS
27 RECENT EVENTS AND ANALYST OPINION
27 Ampion for Osteoarthritis and Osteoarthritis Pain (September 15, 2021)
27 AmnioFix for Osteoarthritis and Osteoarthritis Pain (September 13, 2021)
29 Tanezumab for Osteoarthritis and Osteoarthritis Pain (March 25, 2021)
30 Tanezumab for Osteoarthritis and Osteoarthritis Pain (March 22, 2021)
31 GLPG1972 for Osteoarthritis and Osteoarthritis Pain (October 15, 2020)
33 Fasinumab for Osteoarthritis and Osteoarthritis Pain (August 18, 2020)
34 UBX0101 for Osteoarthritis and Osteoarthritis Pain (August 17, 2020)
35 Fasinumab for Osteoarthritis and Osteoarthritis Pain (August 5, 2020)
37 Otenaproxesul for Osteoarthritis and Osteoarthritis Pain (June 1, 2020)
39 KEY UPCOMING EVENTS
40 KEY REGULATORY EVENTS
40 Pfizer/Lilly Discontinue Tanezumab, The Likely End For A Class Dogged By Safety
40 Tanezumab Receives Negative CHMP Opinion
40 US Fast-Track For OA Knee Therapy
40 Pfizer’s Tanezumab REMS Cannot Make Benefit-Risk Positive, US FDA Panel Says
41 Pfizer’s Tanezumab REMS Faces US FDA Doubts Heading Into Panel Review
41 Medipost Accelerates Global Push For Lead Stem Cell Therapy
42 PROBABILITY OF SUCCESS
43 LICENSING AND ASSET ACQUISITION DEALS
43 Pacira Aims For Non-Opioid Pipeline Growth With Flexion Buy
43 Biosplice Finds China Partner For Knee Osteoarthritis Drug In Haisco
43 Samil Gets South Korean Rights To Biosplice’s Knee Arthritis Compound
43 LG Chem Expands Into Gene Therapy Via ICM Agreement
45 REVENUE OPPORTUNITY
47 CLINICAL TRIAL LANDSCAPE
48 Sponsors by status
49 Sponsors by phase
50 Recent events
51 BIBLIOGRAPHY
52 APPENDIX
LIST OF FIGURES
13 Figure 1: Trends in prevalent cases of osteoarthritis (knee or hip), 2019–28
18 Figure 2: Overview of pipeline drugs for osteoarthritis in the US
18 Figure 3: Pipeline drugs for osteoarthritis, by company
19 Figure 4: Pipeline drugs for osteoarthritis, by drug type
19 Figure 5: Pipeline drugs for osteoarthritis, by classification
29 Figure 6: AmnioFix for Osteoarthritis and Osteoarthritis Pain (September 13, 2021): Phase IIb – dHACM (Knee Osteoarthritis)
33 Figure 7: GLPG1972 for Osteoarthritis and Osteoarthritis Pain (October 15, 2020): Phase II – ROCCELLA
35 Figure 8: UBX0101 for Osteoarthritis and Osteoarthritis Pain (August 17, 2020): Phase II – Moderate to Severe Knee OA
37 Figure 9: Fasinumab for Osteoarthritis and Osteoarthritis Pain (August 5, 2020): Phase III – FACT OA1, Phase III – FACT OA2
38 Figure 10: Otenaproxesul for Osteoarthritis and Osteoarthritis Pain (June 1, 2020): Phase IIb – Dose-Ranging
39 Figure 11: Key upcoming events in osteoarthritis
42 Figure 12: Probability of success in the osteoarthritis and osteoarthritis pain pipeline
47 Figure 13: Clinical trials in osteoarthritis
47 Figure 14: Top 10 drugs for clinical trials in osteoarthritis
48 Figure 15: Top 10 companies for clinical trials in osteoarthritis
48 Figure 16: Trial locations in osteoarthritis
49 Figure 17: Osteoarthritis trials status
50 Figure 18: Osteoarthritis trials sponsors, by phase
LIST OF TABLES
12 Table 1: Prevalent cases of osteoarthritis (knee or hip), 2019–28
15 Table 2: Marketed drugs for osteoarthritis
20 Table 3: Pipeline drugs for osteoarthritis in the US
27 Table 4: Ampion for Osteoarthritis and Osteoarthritis Pain (September 15, 2021)
28 Table 5: AmnioFix for Osteoarthritis and Osteoarthritis Pain (September 13, 2021)
30 Table 6: Tanezumab for Osteoarthritis and Osteoarthritis Pain (March 25, 2021)
31 Table 7: Tanezumab for Osteoarthritis and Osteoarthritis Pain (March 22, 2021)
32 Table 8: GLPG1972 for Osteoarthritis and Osteoarthritis Pain (October 15, 2020)
33 Table 9: Fasinumab for Osteoarthritis and Osteoarthritis Pain (August 18, 2020)
34 Table 10: UBX0101 for Osteoarthritis and Osteoarthritis Pain (August 17, 2020)
36 Table 11: Fasinumab for Osteoarthritis and Osteoarthritis Pain (August 5, 2020)
37 Table 12: Otenaproxesul for Osteoarthritis and Osteoarthritis Pain (June 1, 2020)
45 Table 13: Historical global sales, by drug ($m), 2016–20
46 Table 14: Forecasted global sales, by drug ($m), 2021–25
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Market Spotlight: Neuropathic Pain 
Sign up to the